anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

234,421-234,480 of 319,975

filter-aware
27
Uses a 2x2 grid layout to present four key performance indicators.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
28
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
29
This is a closing slide for an investor presentation.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
30
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
31
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
32
The table includes a footnote regarding non-recurring share listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
33
The table shows adjustments for share-based compensation and depreciation & amortization to arrive at non-IFRS metrics.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
34
The table provides a clear breakdown of non-cash and non-recurring items used to adjust the operating loss.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
35
The table shows a significant increase in operating loss in 2023, largely driven by share-listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
36
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
37
The table details non-cash and non-recurring items to arrive at Adjusted EBITDA.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
38
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
39
The slide uses a structured table to explain how network effects are being scaled.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
01
Slide 1
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
02
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
03
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
04
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
05
The slide uses a Gantt-style visualization to show the progress of various drug candidates through clinical phases.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Need1 hit
06
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Need1 hit
07
Includes a cytogenetic map showing the 600kb deletion region on chromosome 3.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
08
Uses a 'brake pedal' analogy to explain biological function.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
09
The slide uses a process diagram to illustrate the mechanism of action for REQORSA gene therapy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
10
The process is presented as a sequential workflow.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
11
The slide uses a hub-and-spoke visual metaphor to connect the central platform to three key value propositions.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
12
The slide uses a numbered list format to explain the mechanism of action.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
13
The slide uses a line chart (Seahorse XF Glycolysis Stress Test profile) and a bar chart to show metabolic impact.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
14
The slide uses a series of circles to present key metrics, highlighting the global market size as the central focus.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
15
ONC-001 TrialGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
16
The slide uses fluorescence microscopy images to show the mechanism of action (selective uptake) of the drug.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
17
The trial met Simon 2-stage criteria but was discontinued to prioritize a study with Tagrisso.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
18
The slide uses a 'problem-solution' framing, highlighting the limitation of existing drugs and the mechanism of the company's therapy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
19
The slide includes a timeline of the study and two line charts showing tumor volume over time for different treatment groups.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
20
The slide outlines a multi-phase clinical trial structure (Phase 1, 2a, 2b) and provides specific patient counts and interim analysis milestones.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
21
Includes a table of enrollment/DLTs and a swimmer plot for PFS.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
22
Includes a histological image showing negative TUSC2 expression.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
23
The table highlights a statistically significant difference (p=0.0008) in TUSC2 protein expression between SCLC and NSCLC.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
24
Includes Kaplan-Meier curves for Overall Survival (A) and Progression-free Survival (B).Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
25
Kaplan-Meier survival curve showing PFS. Mentions Tecentriq as brand name for Atezolizumab.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
26
Includes bioluminescence imaging and quantitative bar chart with statistical significance markers (p-values).Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
27
The slide shows four separate bar charts comparing Control, Atezo (Tecentriq), REQORSA, and Combination therapies across four immune cell types.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
28
Clinical trial design slide for a pharmaceutical study.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
29
The chart shows statistical significance (p-values) comparing treatment groups against controls.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
30
The chart shows tumor volume over time (days) for four groups, demonstrating synergistic efficacy of the dual gene therapy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
31
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
32
The slide uses a series of circles to present key metrics, highlighting the global expenditure figure.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
33
Uses an emotional image of a father and child to emphasize the human impact of the disease.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
34
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
35
Uses a timeline to establish a 'gap' in innovation, followed by three key arguments for why new therapy is needed.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
36
The slide uses a pie chart to illustrate the prevalence split between T1D and T2D.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
37
Includes a scientific diagram illustrating the transition from hyperglycemia (beta-cell deficiency) to euglycemia (restored beta-cell mass) via AAV-mediated gene delivery.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
38
The slide compares AAV8-PM (therapeutic) against AAV8-GFP (control) and an untreated control group.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
39
The slide uses a comparative analogy between mouse lifespan and human lifespan to suggest long-term efficacy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
40
The slide uses a combination of a process description (left) and experimental data (line chart and bar chart) to validate the therapeutic hypothesis.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Visualization1 hit
41
NHP = Non-Human Primate. STZ likely refers to Streptozotocin, a compound used to induce diabetes in animal models.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
42
ATTD likely refers to the Advanced Technologies & Treatments for Diabetes conference.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
43
The data shows a significant improvement in glucose regulation post-therapy, closely tracking the normal NHP curve.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
44
IHC stands for Immunohistochemistry. The images show DAPI (blue), Insulin (cyan), and Glucagon (red) staining.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
45
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
46
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit
47
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations 1 hit